San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Hims & Hers (NYSE: HIMS) is attracting investors looking to buy the dip in this impressive growth stock. Where to invest ...

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Novo Nordisk has ended a partnership with telehealth company Him & Hers, after launching the collaboration less than two ...